<DOC>
	<DOCNO>NCT00245037</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , fludarabine busulfan , donor peripheral blood stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain cancer cell ( graft-versus-tumor effect ) . Giving infusion donor 's T cell ( donor lymphocyte infusion ) transplant may help increase effect . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This phase I/II trial study side effect give busulfan fludarabine together total-body irradiation see well work treat patient undergo donor stem cell transplant hematologic cancer .</brief_summary>
	<brief_title>Busulfan , Fludarabine , Total-Body Irradiation Treating Patients Who Are Undergoing Donor Stem Cell Transplant Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess safety toxicity addition busulfan add establish fludarabine low-dose total-body irradiation ( TBI ) condition regimen non-myeloablative allogeneic transplantation patient hematologic malignancy . ( Phase I ) - To assess non-relapse mortality 1-year conditioning busulfan fludarabine/TBI patient hematologic malignancy moderate high risk graft rejection and/or relapse underlying disease . ( Phase II ) Secondary - To assess overall survival 1-year survival . ( Phase II ) - To assess incidence graft rejection . ( Phase II ) - To assess incidence grade II-IV acute graft-vs-host disease ( GVHD ) chronic extensive GVHD . ( Phase II ) - To assess rate disease progression and/or relapse-related mortality . ( Phase II ) - To determine non-hematologic grade III-IV organ specific toxicity . ( Phase II ) OUTLINE : - Nonmyeloablative-conditioning regimen : Patients receive busulfan IV day -5 fludarabine IV 30 minute day -4 -2 . Patients undergo total body irradiation day 0 . - Allogeneic peripheral blood stem cell transplantation ( PBSC ) : Patients undergo donor PBSC infusion day 0 . - Graft-versus-host disease prophylaxis : Patients receive oral cyclosporine twice daily day -3 56 followed taper day 180 . Patients related stem cell donor receive oral mycophenolate mofetil twice daily day 0-28 . Patients unrelated stem cell donor receive oral mycophenolate mofetil 3 time daily day 0-28 followed taper twice daily day 56 . Patients evidence relapse persistent disease may also receive 3 donor lymphocyte infusion . PROJECTED ACCRUAL : A total 225 patient accrue study ; 25 patient accrued Phase I 200 patient Phase II .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Phenytoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis hematologic malignancy 1 follow highrisk type : Acute lymphoblastic leukemia Acute myeloid leukemia Chronic myelogenous leukemia Chronic lymphocytic leukemia Myelodysplastic syndrome Myeloproliferative disorder Multiple myeloma Plasma cell dyscrasia NonHodgkin lymphoma Hodgkin disease PATIENT CHARACTERISTICS : Performance status Karnofsky 50100 % Life expectancy Not specify Hematopoietic Not specify Hepatic No liver failure No cirrhosis evidence portal hypertension No alcoholic hepatitis No esophageal varices No chronic hepatitis No liver disease Renal Not specify Cardiovascular Left Ventricular Ejection Fraction ( LVEF ) &gt; 35 % No symptomatic coronary artery disease cardiac failure require therapy Pulmonary Diffusing capacity lung carbon monoxide ( DLCO ) &gt; 30 % Total lung capacity &gt; 30 % Forced expiratory volume 1 second ( FEV_1 ) &gt; 30 % No supplementary continuous oxygen Other HIV negative No active nonhematologic malignancy except localized skin cancer No overt organ dysfunction PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia , breakpoint cluster region-Abelson ( BCR-ABL ) negative</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
</DOC>